Dexmethylphenidate is the dextrorotary form of methylphenidate. It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant. It is used for treatment of Attention Deficit Hyperactivity Disorder (ADHD).
Dexmethylphenidate (d-MPH) hydrochloride is a D-threo enantiomer of racemic D,L-methylphenidate with an approximately tenfold greater potent pharmacological effect than L-methylphenidate.
Dexmethylphenidate (the threo-(R,R)-isomer of methylphenidate) has been extensively shown to be wholly responsible for the DAT-mediated physiological effects of the racemate ,  and was therefore selected for modeling.
The 6-month, open-label follow-up trial primarily evaluated the safety effects of patients taking Dexmethylphenidate for an extended period of time.
In summary, the positive treatment effect of Dexmethylphenidate from the double-blinded phase was maintained throughout the 6 months.
MPH and Dexmethylphenidate have proven to be effective on all ADHD symptoms, including inattentive and hyperactive/impulsive symptoms.
It is important for clinicians to understand that treatment effects with MPH and Dexmethylphenidate can be seen as early as the first week of treatment.
In Switzerland Dexmethylphenidate XR was licensed for use in adults in 2009 and this has been reported as a safe and effective option .